documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
19,752 rows where agency_id = "FDA" and document_type = "Notice" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: posted_date (date), comment_end_date (date), last_modified (date)
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2025-N-0421-0002 | FDA | NOOH Proposal to Debar Oscar Bobo FDA-2025-N-0421 | Oscar Bobo: Final Debarment Order | Notice | Statutory Debarment | 2026-05-15T04:00:00Z | 2026 | 5 | 2026-05-15T04:00:00Z | 2026-05-15T17:48:54Z | 2026-09767 | 1 | 0 | 09000064b92da9bd | |
| FDA-2026-N-4126-0001 | FDA | Azodicarbonamide (ADA); Request for Information FDA-2026-N-4126 | Azodicarbonamide (ADA); Request for Information | Notice | Requests for Information (RFI) | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-07-14T03:59:59Z | 2026-05-13T17:13:38Z | 2026-09508 | 1 | 0 | 09000064b92d17fd |
| FDA-2026-N-3098-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting FDA-2026-N-3098 | Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting | Notice | 60 Day Proposed Information Collection | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-07-14T03:59:59Z | 2026-05-13T16:56:28Z | 2026-09543 | 1 | 0 | 09000064b92d4966 |
| FDA-2026-N-2526-0001 | FDA | Butylated hydroxytoluene (BHT); Request for Information FDA-2026-N-2526 | Butylated Hydroxytoluene (BHT); Request for Information | Notice | Requests for Information (RFI) | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-07-14T03:59:59Z | 2026-05-13T17:01:00Z | 2026-09507 | 1 | 0 | 09000064b92d4931 |
| FDA-2019-N-0994-0230 | FDA | Modified Risk Tobacco Product Applications for VLN™ King and VLN™ Menthol King, Combusted, Filtered Cigarettes, Submitted by 22nd Century Group Inc. FDA-2019-N-0994 | Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc. | Notice | Request for Comments | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-05-15T09:00:24Z | 2026-09544 | 1 | 0 | 09000064b92d47df | |
| FDA-2025-N-1600-0003 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3 FDA-2025-N-1600 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3 | Notice | 30 Day Proposed Information Collection | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-06-13T03:59:59Z | 2026-05-13T17:17:21Z | 2026-09448 | 1 | 0 | 09000064b92d4828 |
| FDA-2026-N-0005-0001 | FDA | Public Seminar FDA-2026-N-0005 | Biomarker Incubator: Urinary Kidney Safety Biomarkers; Request for Information | Notice | Requests for Information (RFI) | 2026-05-13T04:00:00Z | 2026 | 5 | 2026-05-13T04:00:00Z | 2026-07-14T03:59:59Z | 2026-05-13T17:06:21Z | 2026-09533 | 1 | 0 | 09000064b92d48f3 |
| FDA-2026-N-4492-0001 | FDA | Drug Repurposing for Unmet Medical Needs; Request for Information FDA-2026-N-4492 | Drug Repurposing for Unmet Medical Needs; Request for Information | Notice | Requests for Information (RFI) | 2026-05-12T04:00:00Z | 2026 | 5 | 2026-05-12T04:00:00Z | 2026-06-12T03:59:59Z | 2026-05-15T09:00:24Z | 2026-09366 | 1 | 0 | 09000064b92d15f4 |
| FDA-2017-N-5925-0040 | FDA | Standard Development Organizations Whose Susceptibility Test Interpretive Criteria Standards May Be Recognized by FDA FDA-2017-N-5925 | 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria web page | Notice | Request for Comments | 2026-05-12T04:00:00Z | 2026 | 5 | 2026-05-12T04:00:00Z | 2026-05-12T22:58:36Z | 2026-09438 | 1 | 0 | 09000064b92d17af | |
| FDA-2026-D-5083-0001 | FDA | Enforcement Policies for Certain Electronic Nicotine Delivery Systems (ENDS) Marketed Without Premarket Authorization; Guidance for Industry; Availability FDA-2026-D-5083 | Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability | Notice | Notice of Availability | 2026-05-12T04:00:00Z | 2026 | 5 | 2026-05-12T04:00:00Z | 2026-05-12T17:17:05Z | 2026-09368 | 0 | 0 | 09000064b92d1762 | |
| FDA-2025-N-2220-0002 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products FDA-2025-N-2220 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products | Notice | 30 Day Proposed Information Collection | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-06-11T03:59:59Z | 2026-05-11T21:25:31Z | 2026-09244 | 1 | 0 | 09000064b92cfa18 |
| FDA-2011-N-0655-0042 | FDA | Animal Generic Drug User Fee Act; Public Meeting FDA-2011-N-0655 | Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate | Notice | Notice of Intent | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T21:26:21Z | 2026-09284 | 0 | 0 | 09000064b92cf91b | |
| FDA-2026-N-4573-0001 | FDA | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm) FDA-2026-N-4573 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm) | Notice | Announcement | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T17:34:15Z | 2026-09242 | 0 | 0 | 09000064b92cf987 | |
| FDA-2013-D-1319-0015 | FDA | Draft Guidance for Industry on Pulmonary Tuberculosis: Developing Drugs for Treatment; Availability FDA-2013-D-1319 | Pulmonary Tuberculosis: Developing Drugs for Treatment; Guidance for Industry; Availability | Notice | Notice of Availability | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T17:27:37Z | 2026-09269 | 0 | 0 | 09000064b92cf98a | |
| FDA-2018-D-4693-0022 | FDA | Postapproval Pregnancy Safety Studies; Draft Guidance for Industry; Availability FDA-2018-D-4693 | Postapproval Pregnancy Safety Studies; Guidance for Industry; Availability | Notice | Notice of Availability | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T17:36:17Z | 2026-09268 | 0 | 0 | 09000064b92cf982 | |
| FDA-2011-N-0656-1315 | FDA | Animal Drug User Fee Act; Public Meeting FDA-2011-N-0656 | Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate | Notice | General Notice | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T17:56:32Z | 2026-09283 | 0 | 0 | 09000064b92cacd0 | |
| FDA-2022-D-1261-0003 | FDA | Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention; Draft Guidance for Industry; Availability FDA-2022-D-1261 | Clostridioides Difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, or Prevention; Guidance for Industry; Availability | Notice | Notice of Availability | 2026-05-11T04:00:00Z | 2026 | 5 | 2026-05-11T04:00:00Z | 2026-05-11T17:42:11Z | 2026-09267 | 0 | 0 | 09000064b92cf922 | |
| FDA-2026-P-0749-0004 | FDA | Requests that the FDA determine whether Leucovorin Calcium For Oral Solution, EQ 60 mg base/vial, (NDA 008107) held by Hospira Inc. has been voluntarily withdrawn or withheld from sale for reasons of safety or efficacy FDA-2026-P-0749 | Determination That Leucovorin Calcium, Oral Solution, Equivalent to 60 Milligrams Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-05-08T04:00:00Z | 2026 | 5 | 2026-05-08T17:04:13Z | 2026-09199 | 0 | 0 | 09000064b92c97d0 | ||
| FDA-2025-P-7054-0006 | FDA | Request that the FDA determine whether the Reference Listed Drug (RLD) MICARDIS (Telmisartan Tablets, 20 mg and 80 mg) under New Drug Application (NDA) N020850 held by Boehringer Ingelheim, was voluntarily withdrawn from commercial distribution or withdrawn from sale for safety or efficacy reasons FDA-2025-P-7054 | Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-05-07T04:00:00Z | 2026 | 5 | 2026-05-07T04:00:00Z | 2026-05-07T17:15:35Z | 2026-09011 | 0 | 0 | 09000064b92c66bf | |
| FDA-2023-D-2370-0007 | FDA | Patient-Matched Guides to Orthopedic Implants; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance for Industry and Food and Drug Administration Staff; Availability FDA-2023-D-2370 | Patient-Matched Guides for Orthopedic Implants; Guidance for Industry and Food and Drug Administration Staff; Availability | Notice | Notice of Availability | 2026-05-07T04:00:00Z | 2026 | 5 | 2026-05-07T04:00:00Z | 2026-05-07T17:05:32Z | 2026-09023 | 0 | 0 | 09000064b92c78fc | |
| FDA-2026-N-4291-0001 | FDA | Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications FDA-2026-N-4291 | Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications | Notice | Withdrawal | 2026-05-07T04:00:00Z | 2026 | 5 | 2026-05-07T04:00:00Z | 2026-05-07T16:54:25Z | 2026-09012 | 0 | 0 | 09000064b92c85aa | |
| FDA-2026-N-0008-0004 | FDA | Advisory Committee FDA-2026-N-0008 | Advisory Committee; Blood Products Advisory Committee; Renewal | Notice | Notice of Renewal | 2026-05-07T04:00:00Z | 2026 | 5 | 2026-05-07T04:00:00Z | 2026-05-07T17:02:15Z | 2026-09108 | 0 | 0 | 09000064b92c85a3 | |
| FDA-2026-N-4588-0001 | FDA | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha) FDA-2026-N-4588 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; OTARMENI (lunsotogene parvec-cwha) | Notice | Announcement | 2026-05-06T04:00:00Z | 2026 | 5 | 2026-05-06T04:00:00Z | 2026-05-06T17:40:41Z | 2026-08913 | 0 | 0 | 09000064b92c5bca | |
| FDA-2026-P-1306-0004 | FDA | Requests that the FDA to determine whether the Reference Listed Drug (RLD) DEXAMETHASONE ELIXIR, 0.5 mg/5 mL; Abbreviated New Drug Application (ANDA) 088254 of PHARMOBEDIENT CONSULTING has been voluntarily withdrawn from sale for safety or efficacy reasons. FDA-2026-P-1306 | Determination That DEXAMETHASONE (Dexamethasone) Elixir, 0.5 Milligrams/5 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-05-06T04:00:00Z | 2026 | 5 | 2026-05-06T04:00:00Z | 2026-05-06T17:34:01Z | 2026-08939 | 0 | 0 | 09000064b92c65a4 | |
| FDA-2026-N-3070-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; National Youth Tobacco Survey FDA-2026-N-3070 | Agency Information Collection Activities; Proposed Collection; Comment Request; National Youth Tobacco Survey | Notice | 60 Day Proposed Information Collection | 2026-05-04T04:00:00Z | 2026 | 5 | 2026-05-04T04:00:00Z | 2026-07-07T03:59:59Z | 2026-05-04T19:19:25Z | 2026-08604 | 1 | 0 | 09000064b92c115c |
| FDA-2018-N-3240-0377 | FDA | List of Bulk Drug Substances For Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Notice FDA-2018-N-3240 | List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act | Notice | Request for Comments | 2026-05-01T04:00:00Z | 2026 | 5 | 2026-05-01T04:00:00Z | 2026-07-01T03:59:59Z | 2026-05-16T09:00:17Z | 2026-08552 | 1 | 0 | 09000064b92bb724 |
| FDA-2026-N-3499-0001 | FDA | Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments FDA-2026-N-3499 | Obesity and Drug Dosing: Clinical Pharmacology Considerations; Request for Comments | Notice | Request for Comments | 2026-05-01T04:00:00Z | 2026 | 5 | 2026-05-01T04:00:00Z | 2026-07-01T03:59:59Z | 2026-05-02T09:00:17Z | 2026-08521 | 1 | 0 | 09000064b92bb7fb |
| FDA-2026-N-3947-0001 | FDA | Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments FDA-2026-N-3947 | Impacts of Patient-Focused Drug Development Meetings; Establishment of a Public Docket; Request for Information and Comments | Notice | Request for Comments | 2026-05-01T04:00:00Z | 2026 | 5 | 2026-05-01T04:00:00Z | 2026-07-01T03:59:59Z | 2026-05-09T09:00:22Z | 2026-08524 | 1 | 0 | 09000064b92bb6d7 |
| FDA-2026-N-4268-0001 | FDA | Medical Devices; Exemptions from Premarket Notification: Certain Class II Devices; Request for Comments FDA-2026-N-4268 | Medical Devices; Exemptions From Premarket Notification: Certain Class II Devices; Request for Comments | Notice | Request for Comments | 2026-05-01T04:00:00Z | 2026 | 5 | 2026-05-01T04:00:00Z | 2026-07-01T03:59:59Z | 2026-05-09T09:00:22Z | 2026-08499 | 1 | 0 | 09000064b92bb7b3 |
| FDA-2026-P-0655-0003 | FDA | Request that the FDA determine that the listed RLD product FENOGLIDE (fenofibrate) Tablets, 40 mg and 120 mg, N022118, NDA Holder– Salix Pharmaceuticals INC, was not discontinued for safety or effectiveness reasons FDA-2026-P-0655 | Determination FENOGLIDE (Fenofibrate) Tablets, 40 Milligrams and 120 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T17:56:39Z | 2026-08390 | 0 | 0 | 09000064b92b7f6c | ||
| FDA-2026-N-0499-0002 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice FDA-2026-N-0499 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Hazard Analysis and Critical Control Point Procedures for the Safe and Sanitary Processing and Importing of Juice | Notice | 30 Day Proposed Information Collection | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T04:00:00Z | 2026-06-02T03:59:59Z | 2026-04-30T17:46:42Z | 2026-08417 | 1 | 0 | 09000064b92b80f2 |
| FDA-2026-N-0008-0003 | FDA | Advisory Committee FDA-2026-N-0008 | Advisory Committee; Pharmacy Compounding Advisory Committee; Renewal | Notice | Notice of Renewal | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T18:03:08Z | 2026-08378 | 0 | 0 | 09000064b92b7f20 | ||
| FDA-2025-P-3849-0004 | FDA | Requests that the FDA determine whether OZEMPIC (semaglutide) Injection, 2 mg/1.5 mL (1.34 mg/mL) was withdrawn for safety or effectiveness reasons. FDA-2025-P-3849 | Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T18:12:42Z | 2026-08435 | 0 | 0 | 09000064b92b5df8 | ||
| FDA-2026-N-3532-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies FDA-2026-N-3532 | Agency Information Collection Activities; Proposed Collection; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies | Notice | 60 Day Proposed Information Collection | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T04:00:00Z | 2026-06-30T03:59:59Z | 2026-05-02T09:00:17Z | 2026-08371 | 1 | 0 | 09000064b92b7fb3 |
| FDA-2026-N-1321-0001 | FDA | ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing FDA-2026-N-1321 | ChemoCentryx, Inc.; Proposal To Withdraw Approval of New Drug Application for TAVNEOS (Avacopan) Capsule, 10 Milligrams; Opportunity for a Hearing | Notice | Withdrawal | 2026-04-30T04:00:00Z | 2026 | 4 | 2026-04-30T04:00:00Z | 2026-06-30T03:59:59Z | 2026-05-16T09:00:16Z | 2026-08455 | 1 | 0 | 09000064b92b7e81 |
| FDA-2026-N-4390-0001 | FDA | AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information FDA-2026-N-4390 | AI-Enabled Optimization of Early- Phase Clinical Trials Pilot Program; Request for Information | Notice | Requests for Information (RFI) | 2026-04-29T04:00:00Z | 2026 | 4 | 2026-04-29T04:00:00Z | 2026-05-30T03:59:59Z | 2026-05-16T12:32:04Z | 2026-08281 | 1 | 0 | 09000064b92b54c8 |
| FDA-2026-N-1832-0014 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1303 - Bifidobacterium animalis subsp. lactis CGMCC5470 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:48Z | 0 | 0 | 09000064b92a8cd6 | ||
| FDA-2025-N-1928-0067 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1279 – Saccharomyces cerevisiae CCTCC M2025194 – amendments | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:24:49Z | 0 | 0 | 09000064b92a80fa | ||
| FDA-2026-N-1832-0008 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 3 of 3 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:28:45Z | 0 | 0 | 09000064b92a8ccc | ||
| FDA-2025-N-1928-0066 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1278 – Lactiplantibacillus plantarum CGMCC 6312 – amendments | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:24:47Z | 0 | 0 | 09000064b92a80f9 | ||
| FDA-2025-N-1928-0064 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1256 – Lemna leaf protein – amendments | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:18:46Z | 0 | 0 | 09000064b92a80f7 | ||
| FDA-2026-N-1832-0007 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 2 of 3 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:28:26Z | 0 | 0 | 09000064b92a8ccb | ||
| FDA-2025-N-1928-0065 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1276 – Cellulase enzyme preparation produced by Trichoderma reesei expressing a gene encoding a cellulase from Aspergillus niger – amendments | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:24:37Z | 0 | 0 | 09000064b92a80f8 | ||
| FDA-2026-N-1832-0015 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1304 - Preparation containing at least three bacteriophages (phage) specific to Listeria spp. | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:52Z | 0 | 0 | 09000064b92a8cd7 | ||
| FDA-2026-N-1832-0003 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1293 - Brazzein preparation produced by Komagataella phaffii “RA-b” expressing a gene encoding for brazzein from Pentadiplandra brazzeana - Part 2 of 2 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:27:02Z | 0 | 0 | 09000064b92a8cc6 | ||
| FDA-2026-N-1832-0005 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1295 - Brazzein preparation produced by Komagataella phaffii GS115 expressing a gene encoding for brazzein from Pentadiplandra brazzeana | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:27:45Z | 0 | 0 | 09000064b92a8cc9 | ||
| FDA-2025-N-1928-0069 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1296 - Erythritol produced through fermentation of glucose by Yarrowia lipolytica | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:25:01Z | 0 | 0 | 09000064b92a80fc | ||
| FDA-2025-N-1928-0068 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1292 - Citrus-derived compounded sweetener made with neohesperidin dihydrochalcone and gamma cyclodextrin | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:24:59Z | 0 | 0 | 09000064b92a80fb | ||
| FDA-2026-N-1832-0010 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1299 - 3'-Sialyllactose (3'-SL) Sodium Salt | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:24Z | 0 | 0 | 09000064b92a8ccf | ||
| FDA-2026-N-1832-0006 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1297 - Enzyme-hydrolyzed brown rice protein - Part 1 of 3 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:27:58Z | 0 | 0 | 09000064b92a8cca | ||
| FDA-2026-N-1832-0012 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1301 - Algal oil (≥45% docosahexaenoic acid from Schizochytrium sp. “JDW-108”) | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:36Z | 0 | 0 | 09000064b92a8cd4 | ||
| FDA-2026-N-1832-0002 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1293 - Brazzein preparation produced by Komagataella phaffii “RA-b” expressing a gene encoding for brazzein from Pentadiplandra brazzeana - Part 1 of 2 | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:26:49Z | 0 | 0 | 09000064b92a8cc5 | ||
| FDA-2026-N-1832-0004 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1294 - Rebaudioside M produced by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:27:15Z | 0 | 0 | 09000064b92a8cc7 | ||
| FDA-2026-N-1832-0009 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1298 - 2'-fucosyllactose | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:07Z | 0 | 0 | 09000064b92a8ccd | ||
| FDA-2026-N-1832-0013 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1302 - Fermented grape pomace | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:44Z | 0 | 0 | 09000064b92a8cd5 | ||
| FDA-2026-N-1832-0001 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1291 - Wattle Seeds (Acacia longifolia) | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:26:31Z | 0 | 0 | 09000064b92a8cc4 | ||
| FDA-2026-N-1832-0011 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2026 FDA-2026-N-1832 | GRAS Notice (GRN) 1300 – Zeaxanthin | Notice | General Notice | 2026-04-28T04:00:00Z | 2026 | 4 | 2026-04-28T04:00:00Z | 2026-04-28T16:29:32Z | 0 | 0 | 09000064b92a8cd1 | ||
| FDA-2022-N-0621-0003 | FDA | Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal FDA-2022-N-0621 | Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal | Notice | Renewals | 2026-04-27T04:00:00Z | 2026 | 4 | 2026-04-27T17:18:57Z | 2026-08125 | 0 | 0 | 09000064b92ad1da | ||
| FDA-2026-N-3962-0001 | FDA | Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – United States (U.S.) 2026-2027 Formula for COVID-19 Vaccine Composition. FDA-2026-N-3962 | Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments— United States (U.S.) 2026–2027 Formula for COVID–19 Vaccine Composition | Notice | Request for Comments | 2026-04-27T04:00:00Z | 2026 | 4 | 2026-04-27T04:00:00Z | 2026-05-28T03:59:59Z | 2026-05-16T09:00:16Z | 2026-08122 | 1 | 0 | 09000064b92ad21d |
| FDA-2026-N-3445-0001 | FDA | Egis Pharmaceuticals Limited, et al.; Withdrawal of Approval of Three Abbreviated New Drug Applications FDA-2026-N-3445 | Egis Pharmaceuticals Limited, et al.; Withdrawal of Approval of Three Abbreviated New Drug Applications | Notice | Withdrawal | 2026-04-24T04:00:00Z | 2026 | 4 | 2026-04-24T04:00:00Z | 2026-04-24T18:50:43Z | 2026-08020 | 0 | 0 | 09000064b92a8517 | |
| FDA-2026-N-3334-0001 | FDA | Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability FDA-2026-N-3334 | Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability | Notice | Announcement | 2026-04-24T04:00:00Z | 2026 | 4 | 2026-04-24T04:00:00Z | 2026-04-24T18:41:49Z | 2026-08084 | 0 | 0 | 09000064b92a8592 | |
| FDA-2026-N-2642-0001 | FDA | Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments FDA-2026-N-2642 | Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke; Established List Additions and Request for Comments | Notice | Request for Comments | 2026-04-23T04:00:00Z | 2026 | 4 | 2026-04-23T04:00:00Z | 2026-05-27T03:59:59Z | 2026-05-16T09:00:16Z | 2026-07910 | 1 | 0 | 09000064b92a4e3b |
| FDA-2025-N-7055-0002 | FDA | NOOH Proposal to Debar Kimberly Schaff Kiehl FDA-2025-N-7055 | Kimberly Schaff Kiehl: Final Debarment Order | Notice | Statutory Debarment | 2026-04-23T04:00:00Z | 2026 | 4 | 2026-04-23T04:00:00Z | 2026-04-24T19:52:58Z | 2026-07864 | 1 | 0 | 09000064b92a4e3c | |
| FDA-2026-N-2366-0010 | FDA | Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments FDA-2026-N-2366 | Commissioner’s National Priority Voucher (CNPV) Pilot Program; Public Hearing; Request for Comments; Amendment | Notice | Request for Comments | 2026-04-23T04:00:00Z | 2026 | 4 | 2026-04-23T04:00:00Z | 2026-04-23T17:36:23Z | 2026-07916 | 0 | 0 | 09000064b92a4d6f | |
| FDA-2025-D-6130-0001 | FDA | Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry; Availability FDA-2025-D-6130 | Establishing Impurity Specifications for Antibiotics; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T04:00:00Z | 2026-04-20T17:35:59Z | 2026-07629 | 0 | 0 | 09000064b9293df3 | |
| FDA-2025-D-7121-0001 | FDA | Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators; Draft Guidance for Industry and Food and Drug Administration Staff; Availability FDA-2025-D-7121 | Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators; Draft Guidance for Industry and Food and Drug Administration Staff; Availability | Notice | Notice of Availability | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T04:00:00Z | 2026-04-20T17:40:49Z | 2026-07613 | 0 | 0 | 09000064b929309a | |
| FDA-2025-N-6743-2002 | FDA | Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information FDA-2025-N-6743 | Potential New Indication for Testosterone Replacement Therapy | Notice | Announcement | 2026-04-20T04:00:00Z | 2026 | 4 | 2026-04-20T04:00:00Z | 2026-04-20T17:25:47Z | 2026-07615 | 0 | 0 | 09000064b9293dfa | |
| FDA-2026-N-2917-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Qualitative Data to Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed FDA-2026-N-2917 | Agency Information Collection Activities; Proposed Collection; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed | Notice | 60 Day Proposed Information Collection | 2026-04-17T04:00:00Z | 2026 | 4 | 2026-04-17T04:00:00Z | 2026-06-17T03:59:59Z | 2026-04-17T16:47:09Z | 2026-07501 | 1 | 0 | 09000064b9289353 |
| FDA-2011-N-0655-0041 | FDA | Animal Generic Drug User Fee Act; Public Meeting FDA-2011-N-0655 | Animal Generic Drug User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-17T04:00:00Z | 2026 | 4 | 2026-04-17T04:00:00Z | 2027-12-02T04:59:59Z | 2026-04-17T17:16:13Z | 2026-07497 | 1 | 0 | 09000064b928930a |
| FDA-2011-N-0656-1314 | FDA | Animal Drug User Fee Act; Public Meeting FDA-2011-N-0656 | Animal Drug User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-17T04:00:00Z | 2026 | 4 | 2026-04-17T04:00:00Z | 2027-12-02T04:59:59Z | 2026-04-17T17:15:38Z | 2026-07498 | 1 | 0 | 09000064b928948d |
| FDA-2026-N-3099-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Radioactive Drug Research Committees FDA-2026-N-3099 | Agency Information Collection Activities; Proposed Collection; Comment Request; Radioactive Drug Research Committees | Notice | 60 Day Proposed Information Collection | 2026-04-17T04:00:00Z | 2026 | 4 | 2026-04-17T04:00:00Z | 2026-06-17T03:59:59Z | 2026-04-17T16:55:18Z | 2026-07507 | 1 | 0 | 09000064b9289303 |
| FDA-2026-N-3799-0001 | FDA | Authorization of Emergency Use for Four Animal Drugs for the Treatment of New World Screwworm; Availability FDA-2026-N-3799 | Authorization of Emergency Use for Four Animal Drugs for the Treatment of New World Screwworm; Availability | Notice | Announcement | 2026-04-17T04:00:00Z | 2026 | 4 | 2026-04-17T04:00:00Z | 2026-04-17T16:43:08Z | 2026-07509 | 0 | 0 | 09000064b928935b | |
| FDA-2025-E-0501-0006 | FDA | Patent Term Extension Application for UNLOXCYT® (cosibelimab-ipdl), Patent No. 10,590,199 FDA-2025-E-0501 | Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT | Notice | Determinations | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T04:00:00Z | 2026-06-16T03:59:59Z | 2026-04-16T17:49:56Z | 2026-07422 | 1 | 0 | 09000064b928671f |
| FDA-2025-E-0502-0006 | FDA | Patent Term Extension Application for UNLOXCYT® (cosibelimab-ipdl), Patent No. 11,834,505 FDA-2025-E-0502 | Determination of Regulatory Review Period for Purposes of Patent Extension; UNLOXCYT | Notice | Determinations | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T04:00:00Z | 2026-06-16T03:59:59Z | 2026-04-16T17:53:26Z | 2026-07422 | 1 | 0 | 09000064b9286364 |
| FDA-2026-N-3400-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs FDA-2026-N-3400 | Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs | Notice | 60 Day Proposed Information Collection | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T04:00:00Z | 2026-06-16T03:59:59Z | 2026-04-18T09:00:22Z | 2026-07423 | 1 | 0 | 09000064b9286561 |
| FDA-2025-N-6895-0001 | FDA | Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List FDA-2025-N-6895 | Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List | Notice | Request for Comments | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T04:00:00Z | 2026-07-23T03:59:59Z | 2026-05-15T09:00:20Z | 2026-07361 | 1 | 0 | 09000064b92865ab |
| FDA-2021-D-0613-0002 | FDA | CVM GFI #91 (VICH GL8) Stability Testing for Medicated Premixes FDA-2021-D-0613 | International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Stability Testing for Medicated Premixes (Revision 1); Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T18:45:04Z | 2026-07419 | 0 | 0 | 09000064b9286528 | ||
| FDA-2026-N-3466-0001 | FDA | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine) FDA-2026-N-3466 | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine) | Notice | Notice of Approval | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T18:40:24Z | 2026-07370 | 0 | 0 | 09000064b9286529 | ||
| FDA-2025-P-4154-0004 | FDA | Request that the FDA determine whether Chewtadzy (tadalafil) Chewable Tablets, 5 mg, 10 mg, and 20 mg, approved under New Drug Application (NDA) number 218527, held by B Better, LLC, has been voluntarily withdrawn for reasons of safety or effectiveness FDA-2025-P-4154 | Determination That CHEWTADZY (Tadalafil) Chewable Tablets, 5 Milligrams, 10 Milligrams, 20 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T17:43:18Z | 2026-07443 | 0 | 0 | 09000064b92867ad | ||
| FDA-2026-N-3500-0001 | FDA | Notice of Approval of Product Under Priority Review Voucher; Material Threat Medical Countermeasure Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine) FDA-2026-N-3500 | Notice of Approval of Product Under Priority Review Voucher; Material Threat Medical Countermeasure Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine) | Notice | Notice of Approval | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T17:45:21Z | 2026-07369 | 0 | 0 | 09000064b9286771 | ||
| FDA-2026-N-3240-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs FDA-2026-N-3240 | Agency Information Collection Activities; Proposed Collection; Comment Request; Importation of Prescription Drugs | Notice | 60 Day Proposed Information Collection | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T04:00:00Z | 2026-06-16T03:59:59Z | 2026-04-16T18:04:30Z | 2026-07421 | 1 | 0 | 09000064b92866e7 |
| FDA-2025-P-4151-0004 | FDA | Requests that FDA determine whether ReVia (naltrexone HCl) Tablets, 50 mg, approved under New Drug Application (NDA) number 018932, held by Teva Women’s Health, Inc., has been voluntarily withdrawn for reasons of safety or effectiveness FDA-2025-P-4151 | Determination That REVIA (Naltrexone Hydrochloride) Tablets, 50 Milligrams Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T18:24:57Z | 2026-07451 | 0 | 0 | 09000064b928652f | ||
| FDA-2026-N-3446-0001 | FDA | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) FDA-2026-N-3446 | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) | Notice | Notice of Approval | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T18:19:33Z | 2026-07368 | 0 | 0 | 09000064b9286565 | ||
| FDA-2026-N-3447-0001 | FDA | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MNEXSPIKE (COVID-19 Vaccine, mRNA) FDA-2026-N-3447 | Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MNEXSPIKE (COVID–19 Vaccine, mRNA) | Notice | Notice of Approval | 2026-04-16T04:00:00Z | 2026 | 4 | 2026-04-16T18:06:41Z | 2026-07371 | 0 | 0 | 09000064b92866e5 | ||
| FDA-2026-D-1255-0001 | FDA | Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability FDA-2026-D-1255 | Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-04-15T04:00:00Z | 2026 | 4 | 2026-04-15T04:00:00Z | 2026-04-15T17:11:56Z | 2026-07285 | 0 | 0 | 09000064b92810b1 | |
| FDA-2025-N-4731-0052 | FDA | Increasing Availability of Nonprescription Drugs; Request for Information FDA-2025-N-4731 | Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-15T04:00:00Z | 2026 | 4 | 2026-04-23T04:00:00Z | 2026-05-09T03:59:59Z | 2026-05-09T09:00:20Z | 2026-07335 | 0 | 0 | 09000064b9282192 |
| FDA-2026-N-3273-0001 | FDA | Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments” FDA-2026-N-3273 | Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-15T04:00:00Z | 2026 | 4 | 2026-04-15T04:00:00Z | 2026-07-24T03:59:59Z | 2026-04-15T17:05:22Z | 2026-07248 | 1 | 0 | 09000064b9282224 |
| FDA-2025-P-2524-0004 | FDA | Requests that the FDA to determine whether a listed drug was withdrawn from sale for reasons of safety or effectiveness. FDA-2025-P-2524 | Determination That BILTRICIDE (Praziquantel) Oral Tablet, 600 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness | Notice | Determinations | 2026-04-13T04:00:00Z | 2026 | 4 | 2026-04-13T04:00:00Z | 2026-04-13T21:09:10Z | 2026-07059 | 0 | 0 | 09000064b9272b56 | |
| FDA-2026-N-0707-0001 | FDA | GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg base and EQ 25 mg base FDA-2026-N-0707 | GlaxoSmithKline; Withdrawal of Approval of a New Drug Application for Wellcovorin (Leucovorin Calcium) Tablets, EQ 5 mg Base and EQ 25 mg Base | Notice | Withdrawal | 2026-04-10T04:00:00Z | 2026 | 4 | 2026-04-10T04:00:00Z | 2026-04-10T17:40:29Z | 2026-06911 | 0 | 0 | 09000064b926837d | |
| FDA-2026-N-2742-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification FDA-2026-N-2742 | Agency Information Collection Activities; Proposed Collection; Comment Request; Color Additive Certification | Notice | 60 Day Proposed Information Collection | 2026-04-10T04:00:00Z | 2026 | 4 | 2026-04-10T04:00:00Z | 2026-06-10T03:59:59Z | 2026-04-10T18:01:37Z | 2026-06936 | 1 | 0 | 09000064b926825a |
| FDA-2026-N-2743-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503 FDA-2026-N-2743 | Agency Information Collection Activities; Proposed Collection; Comment Request; Submission of Petitions: Food Additive, Color Additive (Including Labeling), Submission of Information to a Master File in Support of Petitions; and Electronic Submission Using Food and Drug Administration Form 3503 | Notice | 60 Day Proposed Information Collection | 2026-04-10T04:00:00Z | 2026 | 4 | 2026-04-10T04:00:00Z | 2026-06-10T03:59:59Z | 2026-04-20T09:00:32Z | 2026-06935 | 1 | 0 | 09000064b926821b |
| FDA-2026-N-2915-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices FDA-2026-N-2915 | Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Approval of Medical Devices | Notice | 60 Day Proposed Information Collection | 2026-04-10T04:00:00Z | 2026 | 4 | 2026-04-10T04:00:00Z | 2026-06-10T03:59:59Z | 2026-04-10T17:47:50Z | 2026-06906 | 1 | 0 | 09000064b9268328 |
| FDA-2025-N-1928-0061 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1283 - Bacillus coagulans BC99 spore preparation - amendment | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:16:57Z | 0 | 0 | 09000064b925c73b | ||
| FDA-2025-N-1928-0063 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1287 - Sucrose oligoesters - amendments | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:17:22Z | 0 | 0 | 09000064b925c73d | ||
| FDA-2025-N-1928-0058 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1266 - Wheat fiber extract from wheat (Triticumaestivum) - amendments | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:16:16Z | 0 | 0 | 09000064b925c737 | ||
| FDA-2025-N-1928-0059 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1271 - Short Chain Fructooligosaccharides - amendments | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:16:28Z | 0 | 0 | 09000064b925c738 | ||
| FDA-2025-N-1928-0060 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1275 - 6'-Sialyllactose sodium salt - amendments | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:16:42Z | 0 | 0 | 09000064b925c73a | ||
| FDA-2025-N-1928-0062 | FDA | Generally Recognized as Safe (GRAS) Notices Filed in 2025 FDA-2025-N-1928 | GRAS Notice (GRN) 1284 - Recombinant bovine lactoferrin isolate produced by Komagataella phaffii “Ppas_337” expressing the gene encoding bovine lactoferrin – amendments | Notice | General Notice | 2026-04-08T04:00:00Z | 2026 | 4 | 2026-04-08T04:00:00Z | 2026-04-08T18:17:10Z | 0 | 0 | 09000064b925c73c | ||
| FDA-2026-N-3058-0001 | FDA | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln) FDA-2026-N-3058 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; LOARGYS (pegzilarginase-nbln) | Notice | Announcement | 2026-04-07T04:00:00Z | 2026 | 4 | 2026-04-07T04:00:00Z | 2026-04-07T18:06:33Z | 2026-06722 | 0 | 0 | 09000064b9256d79 | |
| FDA-2026-N-2431-0001 | FDA | Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings FDA-2026-N-2431 | Agency Information Collection Activities; Proposed Collection; Comment Request; Administrative Practices and Procedures; Formal Hearings | Notice | 60 Day Proposed Information Collection | 2026-04-07T04:00:00Z | 2026 | 4 | 2026-04-07T04:00:00Z | 2026-06-09T03:59:59Z | 2026-05-12T09:00:14Z | 2026-06719 | 1 | 0 | 09000064b9255485 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;